Doubling in the rate of organic growth vs.
Q3: +1.2%
Good resilience of activity in 2020, with
record revenue of €3,922m (+4.9%)
Vaccination campaigns very well received in
nursing homes: two thirds of residents have already been
vaccinated
2021: substantial acceleration in openings
more than 4,000 new beds worldwide
Regulatory News:
The ORPEA Group (Paris:ORP), a world leader in long-term care
(nursing homes, post-acute and rehabilitation hospitals,
psychiatric hospitals and home care services), today announces its
revenue for the 2020 financial year to 31 December and an
acceleration in the opening of new facilities in 2021.
Yves Le Masne, Chief Executive Officer
of ORPEA, said:
“2020 was marked by an unprecedented pandemic primarily
affecting the elderly and frail. The Covid-19 virus has left many
families bereaved, and I would first and foremost like to let them
know, on behalf of all our teams, that they have our support and
our heartfelt thoughts go out to them.
Thanks to the exceptional mobilisation, dedication and
commitment of our staff, who I would again like to thank, and to
the medical, psychological and logistical resources deployed by the
Group, ORPEA is managing to limit the impact of this crisis.
Over the 2020 financial year, ORPEA recorded revenue growth of
almost 5% to €3,922 million.
While the second wave of Covid-19 has led to lockdowns almost
everywhere in Europe, fourth-quarter revenue marked the resilience
of our activity, with the rate of growth accelerating to +6.4%.
Hence, over the final quarter of the year, ORPEA achieved an
increase in activity close to the target defined before the
Covid-19 pandemic, which was +8%.
Although uncertainty is continuing at the beginning of this
year, there are encouraging signs enabling us to be confident in
our gradual growth in 2021: the success of the vaccination campaign
in our nursing homes and the materialisation of our organic growth
strategy, with an increase of over 50% in the opening of new
facilities to more than 4,000 new beds in 13 countries.”
Further upturn in activity in the
fourth quarter
In € millions
Full year
Quarterly
2020
2019
Change
Q4 2020
Q4 2019
Change
France Benelux
2,363.8
2,218.4
+6.6%
625.8
567.7
+10.2%
Central Europe
1,010.7
961.6
+5.1%
254.1
242.7
+4.7%
Eastern Europe
365.6
358.7
+1.9%
95.6
92.3
+3.5%
Iberian Peninsula and Latam
179.0
198.3
-9.8%
40.7
52.5
-22.4%
Other country
3.2
3.1
+3.3%
0.8
0.8
N.A.
Total revenue
3,922.3
3,740.2
+4.9%
1,017.0
956.0
+6.4%
of which: organic growth1
0.0%
+1.2%
Consolidation dates: Clinipsy in
France from 15 July 2020, Sinoué in France from 1st April 2020, TLC
in Ireland from 1st January 2020, SIS Brazil and SIS Portugal from
1st October 2019.
Composition of geographical areas:
France Benelux (France, Belgium, Netherlands, Ireland), Central
Europe (Germany, Italy, Switzerland), Eastern Europe (Austria,
Poland, Czech Republic, Croatia, Slovenia, Latvia), Iberian
Peninsula and Latam (Spain, Portugal, Brazil, Uruguay, Mexico),
Other country (China).
While the fourth quarter was marked by a second wave of the
Covid-19 pandemic and lockdowns in most European countries, the
Group’s activity accentuated its upturn with revenue growth of
+6.4%. During that quarter, organic growth was +1.2%, more than
double that of the previous quarter (+0.5% in Q3). This performance
was a result of:
- the continuing upturn in post-acute and
rehabilitation activities, notably with the transformation of beds
dedicated to Covid-19 patients;
- the solid momentum of mental health
activities;
- good control of occupancy rates in nursing
homes. The teams are continuing to protect everyone via
preventative measures (sectorisation, operating procedures, etc.)
and remedial measures (care protocols, temporary lockdowns, etc.),
which are adapted as new scientific knowledge of the virus becomes
available, while striving to maintain a warm and friendly
ambiance.
With the exception of the Iberian Peninsula and Latam zone,
primarily impacted by Spain, the various geographical areas all
recorded organic growth that was positive or close to zero in the
fourth quarter.
Over 2020 as a whole, which was marked by an unprecedented
pandemic, revenue grew by almost 5% to a record €3,922 million.
This solid performance demonstrates not only the resilience of the
Group’s activity, but also the extraordinary commitment of ORPEA’s
teams to try to limit the impact of this crisis, giving their very
best for our residents and patients. Organic revenue was stable
over the year, growth being a result of the acquisitions of groups,
notably in Ireland in the field of nursing homes and in France in
the field of mental health, as well as targeted acquisitions of
independent facilities.
Success of the deployment of the Covid
vaccine in the Group’s nursing homes
Thanks to the decision taken by most European nations to
prioritise nursing home residents in their vaccine strategies,
vaccination campaigns in the Group’s facilities began at the end of
2020 and significantly accelerated during the first weeks of
January 2021. Once again, the mobilisation of ORPEA’s teams in
terms of educating people about the vaccination strategy, but also
in terms of organisation, has enabled the Group to achieve, as of 8
February 2021, an average vaccination rate of over 66% for its
nursing home residents (those having had at least the first of the
two vaccine injections).
Some countries, such as Spain, Portugal, Brazil, Austria and
Croatia, have already exceeded 80%. This vaccination campaign,
deployed with unprecedented speed, has thus been globally warmly
welcomed by elderly residents and their families and, more
importantly, will protect them from more serious forms of the
disease.
Among the Group’s staff, 37% have already been vaccinated in its
facilities even though, in a number of countries, the campaign is
not yet open to every age bracket.
Whatever the stage of the vaccination programme within the
Group’s facilities, barrier measures, psychological support and all
procedures associated with Covid-19 remain in place to provide
residents, patients, families, staff and external partners with the
best possible protection.
2021: more than 4,000 new beds to
open
Over the last few years, ORPEA has refocused its development
strategy on the most value-creating avenue: the creation of new
facilities in large European and Latin American towns and
cities.
As anticipated, this strategy will begin to bear fruit in 2021,
with an acceleration of over 50% in the opening of new beds
compared with the rate recorded in recent years.
The Group will open, in 2021, and more specifically over the
second half of the year, 4,055 new beds, corresponding to
approximately 45 new facilities and extensions of existing
facilities. These openings will take place across all of the
Group’s geographical zones: 32% in France and Benelux, 20% in
Central Europe, 23% in Eastern Europe and 25% in the Iberian
Peninsula and Latam. These facilities have been designed and built
by the Group incorporating the very highest standards of quality
and care, in compliance with local traditions, and are mostly
located in strategic towns and cities: Antwerp, Porto, Bilbao, Rio,
Villach, Warsaw, Dortmund, Turin, etc.
For example, 2021 will see the opening of the first flagship
ORPEA facility in Brazil with the Peninsula facility, located in
front of the bay in Rio de Janeiro, in one of the city’s most
sought-after districts.
2021 outlook
Although the vaccination campaigns have made a very good start
and the health situation within the Group’s facilities has remained
stable since mid-December, ORPEA remains particularly vigilant and
has recently reinforced its barrier measures, faced with the risk
of new variants of the Covid-19 virus.
ORPEA will indicate its 2021 revenue growth target when it
publishes its 2020 annual results on 16 March.
Financial schedule for
2021
The following dates are subject to change. Press releases will
be published after the market closes.
Event
Date
Full-year 2020 results
Tuesday 16 March 2021
First-quarter 2021 revenue
Tuesday 4 May 2021
Half-year 2021 revenue
Tuesday 20 July 2021
Half-year 2021 results
Tuesday 21 September 2021
Third-quarter 2021 revenue
Wednesday 3 November 2021
About ORPEA (www.orpea-corp.com)
Founded in 1989, ORPEA is one of the major world leaders in
long-term care, with a network of 1,028 facilities comprising
105,443 beds (21,137 of which are under construction) across 22
countries, which are divided into five geographical regions:
- France Benelux: 523 facilities/46,277 beds
(of which 4,957 are under construction)
- Central Europe: 249 facilities/26,491 beds
(of which 4,885 are under construction)
- Eastern Europe: 136 facilities/14,621 beds
(of which 3,647 are under construction)
- Iberian Peninsula/Latin America: 119
facilities/17,914 beds (of which 7,648 are under construction)
- Rest of the world: 1 facility / 140
beds
ORPEA is listed on Euronext Paris (ISIN code: FR0000184798) and
a constituent of the SBF 120, STOXX 600 Europe, MSCI Small Cap
Europe and CAC Mid 60 indices.
1 The Group’s organic growth reflects the following factors: 1.
The year-on-year change in the revenue of existing facilities as a
result of changes in their occupancy rates and per diem rates; 2.
The year-on-year change in the revenue of redeveloped facilities or
those where capacity has been increased in the current or
year-earlier period; 3. Revenue generated in the current period by
facilities created during the year or year-earlier period, and the
change in revenue of recently acquired facilities by comparison
with the previous equivalent period.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209005954/en/
Investor Relations ORPEA Steve Grobet EVP
Communication and Investor Relations s.grobet@orpea.net
Investor Relations NewCap Dusan Oresansky Tel.:
+33 (0)1 44 71 94 94 orpea@newcap.eu
Media Relations Image 7 Laurence Heilbronn Tel.:
+33 (0)6 89 87 61 37 lheibronn@image7.fr
Orpea (EU:ORP)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Orpea (EU:ORP)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024